Abiraterone acetate (Zytiga®) is accepted for use within NHS Scotland

Source:
Scottish Medicines Consortium - SMC
Publisher:
Scottish Medicines Consortium
Publication date:
13 January 2020

Abstract

Abiraterone acetate with prednisone or prednisolone is accepted for use in NHS Scotland for the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer in adult men in combination with androgen deprivation therapy.